Top Markets
#1 Seeker Seeker +53.94%
#2 Helium Helium +51.36%
#3 Pons Pons +32.13%
#4 UnifAI Network UnifAI Network +31.40%
#5 VVS Finance VVS Finance +23.84%
#6 Zylo Ecosystem Zylo Ecosystem +23.74%
#7 TENDIES TENDIES +22.70%
#8 Bounce Bounce +16.46%
#9 DAPPOS DAPPOS +15.70%
#10 Songbird Songbird +15.39%
Coin of the day
Seeker Seeker
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Philogen S.p.A. Philogen S.p.A.

Philogen S.p.A.

PHIL
Kedudukan dalam Saham #10685
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Harga Saham
$27.76
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$801.60M
Perubahan (1 hari)
0.21%
Perubahan (1 tahun)
0.65%
Negara
IT
Perdagangan Philogen S.p.A. (PHIL)

Kategori

Healthcare
Sejarah hasil dividen untuk Philogen S.p.A. (PHIL)
Hasil dividen (TTM) bagi Philogen S.p.A. (simbol saham: PHIL) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Philogen S.p.A. (PHIL) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH